First patient dosed in Onchilles’ Phase I/II trial of N17350

Onchilles Pharma has dosed the first patient in its Phase I/II clinical trial of N17350 for patients with advanced solid tumours. The study is structured to assess the anti-tumour efficacy, biomarker effects, recommended dose, safety and tolerability of N17350. The Phase I/II trial will initially include patients with solid tumours, with planned evaluations of safety and anti-tumour activity. Credit: PaeGAG / Shutterstock.com. Onchilles Pharma has dosed the first patient in its Phase I/II clinical trial of N17350, the lead tumour-directed therapeutic candidate, for patients with advanced solid tumours. The open-label, dose-finding and expansion trial is designed to investigate N17350, which…

Source: Clinical Trials Arena